Get the tools used by (smart)2 investors.

Levered Free Cash Flow for Insulet Corporation

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

PODD: Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform ...

258.75 USD
Price
USD
Fair Value
Upside
160.19 - 289.46
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Insulet Corporation's Levered Free Cash Flow:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-100 M100 M300 M

Performance Summary
  • Insulet's latest twelve months levered free cash flow is 305.4 million
  • Insulet's levered free cash flow for fiscal years ending December 2020 to 2024 averaged 29.32 million.
  • Insulet's operated at median levered free cash flow of -3.9 million from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Insulet's levered free cash flow peaked in December 2024 at 305.4 million.
  • Insulet's levered free cash flow hit its 5-year low in December 2021 of -180 million.
  • Insulet's levered free cash flow decreased in 2021 (-180 million, +300.0%) and increased in 2020 (-45 million, -31.1%), 2022 (-3.9 million, -97.8%), 2023 (70.1 million, -1,897.4%), and 2024 (305.4 million, +335.7%).

How does Insulet's Levered Free Cash Flow benchmark against competitors?

Hide this widget

Metric Usage: Levered Free Cash Flow

Hide this widget
fcf_levered
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM, YTD
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Levered Free Cash Flow in the financials category include:

  • Inventory Long-Term - This item represents the non-current inventories of the motion picture film industry comprising of certain capitalized costs incurred for the acquisition and production of entertainment properties.
  • EBT, Incl. Unusual Items - Represents a company's profitability or loss from its core business activities before considering income taxes
  • Non-Cash Pension Expense - The net amount of expenses paid for employee retirement benefits.
  • EBITDAR - Earnings before interest, taxes, depreciation, amortization, and rent costs (EBITDAR) adjusted for certain one-time items.
View Full List

Search for metric or datapoint

Levered Free Cash Flow

The sum of cash from operations and capital expenditures

Definition of Levered Free Cash Flow

Hide this widget

The Levered Free Cash Flow is calculated as follows:

Cash From Operations
(-) Capital Expenditures
(=) Levered Free Cash Flow

Read more about cash from operations and capital expenditures


Click the link below to download a spreadsheet with an example Levered Free Cash Flow calculation for Insulet Corporation below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-62.257 M-32.257 M-2.257 M39.753 M0200400

The chart above depicts the distribution of levered free cash flow for companies operating in the Healthcare sector in the Developed economic region. Over 3,175 companies were considered in this analysis, and 1,949 had meaningful values. The average levered free cash flow of companies in the sector is -8.804 M with a standard deviation of 17.225 M.

Insulet Corporation's Levered Free Cash Flow of 305.4 M is significantly outside the interquartile range and is excluded from the distribution. The following table provides additional summary stats:

Levered Free Cash Flow In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents3,180
Included Constituents1,949
Min-59.828 M
Max37.325 M
Median-3.932 M
Mean-8.804 M
Standard Deviation17.225 M

You can find companies with similar levered free cash flow using this stock screener.

All rights reserved. Terms Of Use